Arcellx (ACLX) Net Income towards Common Stockholders (2021 - 2025)

Arcellx's (ACLX) quarterly Net Income towards Common Stockholders came in at -$58.0 million in Q4 2025, down 23.34% year-on-year from -$75.7 million in Q4 2024, and down 4.02% quarter-over-quarter from -$55.8 million in Q3 2025.

Arcellx (ACLX) Net Income towards Common Stockholders (2021 - 2025) Analysis & Trends

Arcellx's Net Income towards Common Stockholders history runs 5 years deep, the most recent figure standing at -$58.0 million for Q4 2025.

  • On a quarterly basis, Net Income towards Common Stockholders fell 23.34% year-over-year to -$58.0 million in Q4 2025; TTM through Dec 2025 was -$228.8 million, a 113.33% decrease from a year earlier, with the FY2025 full-year figure at -$228.8 million, down 113.18% from the prior year.
  • Net Income towards Common Stockholders slipped to -$58.0 million in Q4 2025 per ACLX's latest filing, from -$55.8 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $19.8 million in Q4 2023 and bottomed at -$92.9 million in Q3 2022.
  • The 5-year median for Net Income towards Common Stockholders is -$29.1 million (2022), against an average of -$35.0 million.
  • Across the five-year window, Net Income towards Common Stockholders surged 150.89% in 2023 and tumbled 765.1% in 2025, its largest moves.
  • Year by year, Net Income towards Common Stockholders stood at -$59.4 million in 2021, then soared by 34.4% to -$39.0 million in 2022, then jumped by 150.89% to $19.8 million in 2023, then slumped by 337.07% to -$47.0 million in 2024, then retreated by 23.34% to -$58.0 million in 2025.
  • Per Business Quant, the three latest ACLX Net Income towards Common Stockholders figures stand at -$58.0 million (Q4 2025), -$55.8 million (Q3 2025), and -$52.8 million (Q2 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Oculis Holding AG 65,719.23 Bn 65,718.94 Bn - -625.73
2 Nanobiotix 1,933.82 Bn 1,933.76 Bn - -
3 Akari Therapeutics 959.56 Bn 959.56 Bn - -14.46 Mn
4 BeOne Medicines 471.85 Bn 467.06 Bn 1.35 Bn 227.36 Mn
5 Vertex Pharmaceuticals 122.29 Bn 115.04 Bn 2.59 Bn 1.03 Bn
6 Regeneron Pharmaceuticals 70.04 Bn 61.28 Bn 3.31 Bn 727.20 Mn
7 Belite Bio 62.06 Bn 62.06 Bn - -0.68
8 Argenx Se 55.78 Bn 50.60 Bn 1.41 Bn 472.00 Mn
9 Alnylam Pharmaceuticals 37.47 Bn 34.47 Bn 959.66 Mn 205.99 Mn
10 Arcellx 6.48 Bn 6.48 Bn - -58.02 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 -58.02 Mn
Sep 30, 2025 -55.78 Mn
Jun 30, 2025 -52.77 Mn
Mar 31, 2025 -62.27 Mn
Dec 31, 2024 -47.05 Mn
Sep 30, 2024 -25.87 Mn
Jun 30, 2024 -27.16 Mn
Mar 31, 2024 -7.20 Mn
Dec 31, 2023 19.84 Mn
Sep 30, 2023 -39.34 Mn
Jun 30, 2023 -23.84 Mn
Mar 31, 2023 -27.34 Mn
Dec 31, 2022 -38.99 Mn
Sep 30, 2022 -92.87 Mn
Jun 30, 2022 -30.77 Mn
Mar 31, 2022 -26.04 Mn
Dec 31, 2021 -59.44 Mn
Sep 30, 2021 -17.12 Mn
Jun 30, 2021 -15.93 Mn
Mar 31, 2021 -11.28 Mn